Document Detail

RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study.
MedLine Citation:
PMID:  23030660     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Optimum dose ratios of rimabotulinumtoxinB (BTX-B) and onabotulinumtoxinA (BTX-A) have not been determined for forehead wrinkles.
OBJECTIVE: To compare the efficacy and safety of BTX-B and BTX-A for the treatment of forehead lines.
METHODS: Twenty-two women (mean age, 40 years) with symmetrical moderate to severe forehead lines were randomized to receive single intramuscular injections of BTX-A and BTX-B on either side of the forehead, at a potency ratio of 1 : 70 or 1 : 100. Subjects were followed-up for 16 weeks. Four physicians evaluated patients' photographs according to the 4-point Facial Wrinkling Grade (FWG). Clinical Improvement Scale (CIS) was calculated by subtracting FWG score at each visit from that at baseline. Patient satisfaction scores and adverse events were also recorded.
RESULTS: Both BTX-A and BTX-B were effective for the treatment of forehead lines. At both potency ratios, BTX-A had a longer duration of action than BTX-B, while BTX-B led to faster improvement than BTX-A. There was no significant difference in CIS between 700 U and 1000 U BTX-B treatments. Adverse effects were mild and transient.
CONCLUSION: Both BTX-A and BTX-B were effective and well tolerated for the treatment of forehead wrinkles at potency ratios of 1 : 70 and 1 : 100.
D H Lee; S M Kang; A Feneran; C S Youn; J K Kim; S Cho; C H Won; S E Chang; M W Lee; J H Choi; K C Moon
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2012-10-03
Journal Detail:
Title:  Journal of the European Academy of Dermatology and Venereology : JEADV     Volume:  27     ISSN:  1468-3083     ISO Abbreviation:  J Eur Acad Dermatol Venereol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-20     Completed Date:  2013-07-01     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  9216037     Medline TA:  J Eur Acad Dermatol Venereol     Country:  England    
Other Details:
Languages:  eng     Pagination:  e1-7     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Botulinum Toxins / adverse effects,  therapeutic use*
Botulinum Toxins, Type A / adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Drug Administration Schedule
Facial Muscles / drug effects
Injections, Intramuscular
Middle Aged
Patient Satisfaction
Pilot Projects
Prospective Studies
Risk Assessment
Single-Blind Method
Skin Aging / drug effects*
Treatment Outcome
Young Adult
Reg. No./Substance:
0/onabotulinumtoxinA; 0Y70779M1F/rimabotulinumtoxinB; EC Toxins; EC Toxins, Type A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Visual impairment in children with spastic cerebral palsy measured by psychophysical and electrophys...
Next Document:  p53-Pathway activity and apoptosis in hydrogen sulfide-exposed stem cells separated from human gingi...